BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36808598)

  • 21. Follicular lymphoma: 2023 update on diagnosis and management.
    Jacobsen E
    Am J Hematol; 2022 Dec; 97(12):1638-1651. PubMed ID: 36255040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
    Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
    Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
    Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
    Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 26. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India.
    Nair CK; Kurup AR; Manuprasad A; Shenoy PK; Raghavan V
    J Cancer Res Ther; 2021; 17(4):938-942. PubMed ID: 34528545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Leukemization of follicular lymphoma: The features of diagnostic and clinical course of a rare form of the disease].
    Nesterova ES; Kravchenko SK; Mangasarova YK; Plastinina LV; Dvirnyk VN; Kovrigina AM; Shchupletsova IA; Obukhova TN; Gemdzhian EG; Vorobyev IA; Vorobyev AI
    Ter Arkh; 2017; 89(7):45-50. PubMed ID: 28766540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
    Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
    König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
    Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follicular lymphoma: 2018 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2018 Feb; 93(2):296-305. PubMed ID: 29314206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
    Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Hui D; Proctor B; Donaldson J; Shenkier T; Hoskins P; Klasa R; Savage K; Chhanabhai M; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2010 Sep; 51(9):1658-67. PubMed ID: 20795790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 39. Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
    Annunzio K; Bhatta S; Hanel W; Zhao Q; Owen M; Rosen H; Voorhees TJ; Bond DA; Sawalha Y; Sigmund AM; Alinari L; Baiocchi RA; Maddocks KJ; Jones D; Christian B; Epperla N
    Hematol Oncol; 2024 May; 42(3):e3278. PubMed ID: 38726682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.